A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
Hartmut LinkStephen F ThompsonMarc TianJennifer S HaasDominic MeiseChristopher MaasStamen DimitrovPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
Overall, patients treated with pegfilgrastim and lipegfilgrastim were comparable in terms of neutropenia occurrences in the 1-year follow-up. In patients with lymphoma, neutropenia event-related healthcare costs and all-cause hospitalizations were significantly higher with pegfilgrastim compared with lipegfilgrastim in this study; however, this should be interpreted with caution in light of the limited sample size and the absence of clinical information.